Navigation Links
Tranzyme Pharma Presents Initial Phase IIa Data for its Novel,Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis

ion to treat pain, nausea, vomiting, and even malnutrition. Gastroparesis represents a significant unmet medical need as Propulsid(TM) (cisapride), the most widely used product for treating this disorder was removed from the U.S. market in 2000 due to significant cardiovascular adverse effects.

Tranzyme earlier reported that TZP-101 demonstrated excellent tolerability and safety, as well as a desirable pharmacokinetic profile in healthy subjects in two Phase I clinical studies. The Company plans to initiate full Phase II development of TZP-101 for both POI and severe gastroparesis in 3Q 2007. In addition to the ongoing clinical testing of TZP-101 (an intravenous drug), Tranzyme is developing a new oral ghrelin agonist, TZP-102. Tranzyme expects to initiate Phase I clinical testing of TZP-102 in the first quarter of 2008 for the treatment of mild to moderate chronic gastroparesis.

"The Company is making great progress in the development of TZP-101," said Dr. Vipin Garg, President & CEO of Tranzyme Pharma. "Tranzyme's novel ghrelin agonists (TZP-101 and TZP-102) are promising breakthrough drugs with huge commercial potential. Most prokinetic agents under development and on the market act on predominantly central nervous system receptor targets that are also found in the GI tract. Many show potentially serious CNS side effects. Our small molecule ghrelin agonists target a receptor that is more directly involved with regulating gastrointestinal motility."

About Gastroparesis

Gastroparesis results from dysfunction of the nerves of the stomach, leading to postprandial fullness, bloating, early satiety, nausea and vomiting. The three most common etiologies of gastroparesis are diabetes (an estimated 30% of gastroparesis patients), unknown etiology (36%), and post-surgical causes (13%). The prevalence rate of gastroparesis is especially high among diabetic patients, as up to 50% of diabetics worldwide are reported to suffer from gastroparesis
'"/>




Page: 1 2 3

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:5/5/2015)... -- Big Market Research presents a detailed analysis of ... , ( France , Germany , ... and Japan . Current scientific views on the ... 5-year test volume and sales forecasts by country for HAV NAT, ... Delta, HBc Ag, HBe Ag, and ALT/SGPT tests performed in the ...
(Date:5/5/2015)... China , May 5, 2015 Faced with ... rising public health awareness, China,s medical ... the markets with the largest demands have been ... Guangzhou and other first-tier cities. However, the entry ... short time makes these "high-end" markets in first-tier cities increasingly ...
(Date:5/5/2015)... RIDGEFIELD, Conn. , May 5, 2015 /PRNewswire/ ... abstracts from the company,s respiratory portfolio will be ... International Conference taking place May 15-20 in ... therapies for chronic obstructive pulmonary disease (COPD) and ... fibrosis (IPF) and COPD. Of the 29 accepted ...
Breaking Medicine Technology:2015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 22015 Opportunities in the Global Hepatitis Diagnostic Testing Market: Big Market Research 3MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 2MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 3MEDITEXPO JIANGSU 2015 is to Help Medical Device Companies Explore Business Opportunities in Wider Markets 4Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 8Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 9Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 10Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 11Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 12Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 13Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference 14
... Medical Systems Ltd. (Nasdaq: DHRM ) ("Dehaier" or ... and sale of medical devices and homecare medical products in ... the first quarter of fiscal 2011 ended March 31, 2011 ... in the United States. Company management will ...
... LOUIS, April 27, 2011 Stereotaxis, Inc. (Nasdaq: ... of its new Stereotaxis Epoch™  platform, a comprehensive ... recognized benefits of remote magnetic catheter control, the ... power of the Odyssey platform, enabling highly sophisticated ...
Cached Medicine Technology:Dehaier Medical to Report First Quarter 2011 Financial Results on May 4 2Stereotaxis Introduces New Electrophysiology Platform: Epoch™ 2Stereotaxis Introduces New Electrophysiology Platform: Epoch™ 3Stereotaxis Introduces New Electrophysiology Platform: Epoch™ 4
(Date:5/5/2015)... 05, 2015 On May, 5, 2015, My ... musician Irene Rose about alternatives for youngsters to do this ... you get the idea for starting a summer camp and ... an entertainment company called Once Upon a Party and I ... through songs and even scripture. We play games, sing, and ...
(Date:5/5/2015)... RF Technologies®, a leading provider of personal safety ... Solution with Voice Alarms. The ST750 will play a ... wait for assistance when it detects them starting to ... different melodies or tones or silent alerting, by integrating ... Alert®. , For 28 years, Sensatec Fall Management ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Major League ... with the belief that ultimate Frisbee™ is home to ... next sport that engages the world. Nike Ultimate Camps’ ... by creating opportunities for young athletes to learn about ... with MLU the perfect fit. , The Nike Ultimate ...
(Date:5/5/2015)... NovaSom, Inc., announced today that they ... with Ed Begley Jr., airing via Discovery Channel 3rd ... segment will focus on NovaSom, a leader in Obstructive ... their AccuSom® home sleep test, which is the only ... support and next-day test results and interpretation. , ...
(Date:5/5/2015)... Every year, news articles appear warning about the ... dry eye season is spring, also known as allergy season, ... United States. The only season offering a respite from seasonal ... of the Sharon Kleyne Hour™ Power of Water® radio show, ... May 11, 2015. Kleyne is the inventor of Nature’s Tears® ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Hosts Episode Informing People of a True Princess Summer Camp With Irene Rose 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 2Health News:RF Technologies® Releases Sensatec® ST750 Voice Alarm for Fall Management 3Health News:US Sports Camps, Nike Ultimate Camps, and Major League Ultimate Host Youth Ultimate Summer Camps in Philidelphia 2Health News:Innovations with Ed Begley, Jr. to Explore NovaSom, Inc., in Upcoming Episode 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 3
... Robert I. Miller, a 25-year Siemens veteran, ... Industry Group within Siemens IT Solutions and Services, ... http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )In this role, Miller will be ... business plan, including overall go-to-market activities, coordination with ...
... Palmetto GBA, a leading provider of technical and ... by the federal Centers for Medicare & Medicaid Services ... and perform related duties for South Carolina, North Carolina, ... process, CMS awarded Palmetto GBA a contract with a ...
... tomorrow,s (and even today,s) health problems may be found ... Consumer Electronics ShowLAS VEGAS, Jan. 9 /PRNewswire-USNewswire/ ... changing the way we shop, listen to music, and ... However, managing an illness or disability remains a frightening, ...
... strike fear in the hearts of men and those who ... shock of that diagnosis, suffered the grief and anger that ... of a lifetime. In his new book, "Life Begins at ... http://www.authorhouse.com ), he provides a valuable roadmap for those ...
... to Treat Diseases (HTDS) www.htdsmedical.com the company ... (Formerly ReNuYu Biochem) intends to recapitalize to 5 billion ... pending China Bio Chem merger. Consideration for Slavica is ... all doctors involved in Belgrade Serbia research. Key medical ...
... Jan. 8 New York City Mayor Michael R. ... and presented a proclamation to Ilchi Lee, president of ... Education, a revolutionary method of cognitive training to enhance ... is a globally-recognized thought leader regarding the power of ...
Cached Medicine News:Health News:Miller Joins Siemens IT Solutions and Services as V.P. of Healthcare Industry Group 2Health News:CMS Selects Palmetto GBA to Administer Medicare Program in Four States 2Health News:Meridian Makes CES Good For Your Health 2Health News:'Life Begins at 65: Words of a Cancer Survivor': New Book Offers Empowering Strategies for Rising Above Sickness and Setbacks 2Health News:'Life Begins at 65: Words of a Cancer Survivor': New Book Offers Empowering Strategies for Rising Above Sickness and Setbacks 3Health News:Hard To Treat Diseases (HTDS) Recapitalization 2Health News:NYC Mayor Michael R. Bloomberg Declares January 8th 'IBREA Brain Education Day' 2
... Tosoh Corporation launched the first generation HPLC ... HPLC/723Ghb brought a new level of automation ... forefront of diabetes testing in Japan. Now ... system, the G7 offers advanced automation; stable ...
... , Monoclonal antibody method for HbA1c ... study shows 99% agreement with the HPLC ... on a CV of 2.6%* means ... Standardization Program (NGSP) certified method, as recommended ...
... Maximize your laboratorys ... and enhanced automated workflow ... high-throughput automated workstation now ... and immunoassay with specimen ...
The sole coagulation analyzer in the world that uses a unique dry reagent card....
Medicine Products: